

Clinical knowledge management at scale: fulfilling the promise of pervasive computerized clinical decision support for providers and consumers

Roberto A. Rocha, MD, PhD

Sr. Corporate Manager

Clinical Knowledge Management and Decision Support,
Clinical Informatics Research and Development, Partners Healthcare System

Lecturer in Medicine

Division of General Internal Medicine and Primary Care, Department of
Medicine, Brigham and Women's Hospital, Harvard Medical School

2010 MIT SDM Conference on Systems Thinking for Contemporary Challenges

October 22, 2010 @ MIT

Objectives


1. Computerized Clinical Decision Support
 - Modalities of clinical decision support
 - Motivating factors and application results
2. Clinical Knowledge Management System
 - Typical knowledge engineering processes
 - System components and requirements
3. Challenges and opportunities
 - Implementation promises and pitfalls
 - Intra-institutional and inter-institutional

Computerized Clinical Decision Support

Medication order CDS – example 1

Medication Order Active Pt: TEST, TEST

ACETAMINOPHEN - GI Intolerance, Hives, Sulfa - Bronchospasm or Wheezing, Itching, Rash, quinolone - Anaphylaxis, Morphine - Hepatotoxicity, STRAWBERRY - Renal Toxicity,

Med name:  ATORVASTATIN (LIPITOR) Change

Route: PO Pt. To Use Home Supply?

Dose: 80 MG Loading Dose

Frequency: PRN?

Start Time: Today

Duration: Days Doses

Hold if:

Instructions:

DDI Clinical Link

Patient is on Amiodarone and Atorvastatin - May increase Atorvastatin levels resulting in increased risk of myopathy or rhabdomyolysis - Use with caution.

OK Cancel

Computer-generated **Alert** for a
drug-drug interaction (DDI)

Interruptive Alert (force an action)

Drug-Drug Interactions

Drug-drug Interaction

Patient Name: TEST, TEST MRN: 3651718

WARNING!! You may not order these drugs together.
You are ordering **Selegiline Hcl** and patient is currently on **Methylphenidate Hcl Tablet (ritalin Tablet) PO, 10 MG, QD, Today**

Pt. is on Methylphenidate and Selegiline - May increase risk of hypertensive crisis - Concurrent use is contraindicated, Discontinue one of these meds. A 14 day washout period after d/c of MAOI is required before starting Methylphenidate.

Choose one of the following:

☐ Cancel Selegiline Hcl

☐ Discontinue Methylphenidate Hcl Tablet (ritalin Tablet)

Continue

Clinician **must** cancel current order or discontinue pre-existing order

Interruptive Alert (suggest actions)

Drug-Drug Interactions

Drug-related Alerts

Patient Name: TEST, TEST MRN: 3651718

You are ordering: **SOTALOL**. Click here to [Cancel Sotalol](#)

To keep the SOTALOL order, you must respond to each of the interaction alerts below.

Drug-drug Interaction Alerts	Action
<p>Patient is currently on: Levofloxacin PO, 500 MG, Q2H, Today</p> <p>Patient is on Levofloxacin and Sotalol. May result in prolonged QT interval and cardiac arrhythmias. Recommend to avoid concurrent use.</p>	<p><input type="radio"/> Discontinue Levofloxacin</p> <p>Reason for override</p> <p><input type="checkbox"/> Will adjust dose as recommended</p> <p><input type="checkbox"/> Will monitor as recommended</p> <p><input type="checkbox"/> Patient has already tolerated combination</p> <p><input type="checkbox"/> No reasonable alternatives</p> <p><input type="checkbox"/> Other <input type="text"/></p>


[Continue \(Keep SOTALOL\)](#)

Clinician **can** cancel current order, discontinue pre-existing order, or explain current order (override reason)

Medication order CDS – example 2

Medication Order Active Pt: TEST, TEST

ACETAMINOPHEN - GI Intolerance, Hives, Sulfa - Bronchospasm or Wheezing, Itching, Rash, quinolone - Anaphylaxis, Morphine - Hepatotoxicity, STRAWBERRY - Renal Toxicity,

Med name:  ATORVASTATIN (LIPITOR) Change

Route: PO ☐ Pt. To Use Home Supply?

Dose: 80 MG

Frequency:

☐ PRN?

Start Time: Today

Duration: Days Doses

Hold if:

Instructions:

DDI Clinical Link

Patient is on Amiodarone and Atorvastatin - May increase Atorvastatin levels resulting in increased risk of myopathy or rhabdomyolysis - Use with caution.

OK Cancel

Computer-generated Infobutton for a medication (with context)

Context-enabled “Infobuttons”

KnowledgeLink New Search: LIPITOR in meds Patient Info Search

Search Results for LIPITOR

- Micromedex
- A to Z Drug Facts
- ClinicalResource@Ovid
- StatRef!
- Insurer Formulary
- UpToDate
- Access Medicine
- Evidence-based medicine links
- Information for patients
- Partners Handbook
- PCOI
- Google
- Partners Phone Directory
- Partners OnCall Directory

THOMSON MICROMEDEX >> My Thomson Gateway

ATORVASTATIN CALCIUM








Details in DRUGDEX®	ATORVASTATIN
Tradenames	<ul style="list-style-type: none">• Lipitor See Complete Tradename Listing
Class	<ul style="list-style-type: none">• Antihyperlipidemic• HMG-COA Reductase Inhibitor
Adult Dose	<ul style="list-style-type: none">• Diabetes mellitus type 2 - Disease of cardiovascular system, in patients with multiple risk factors for coronary heart disease; Prophylaxis: 10 mg ORALLY once daily• Disease of cardiovascular system, in patients with multiple risk factors for coronary heart disease; Prophylaxis: 10 mg ORALLY once daily• Familial type 3 hyperlipoproteinemia: 10-80 mg ORALLY once daily; evaluate lipid levels after 2-4 wk and adjust doses accordingly• Hyperlipicemia: 10-80 mg ORALLY once daily; evaluate lipid levels after 2-4 wk and adjust doses accordingly• Hypertriglyceridemia: 10-80 mg ORALLY once daily; evaluate lipid levels after 2-4 wk and adjust doses accordingly• Primary hypercholesterolemia: 10-80 mg ORALLY once daily; evaluate lipid levels after 2-4 wk and adjust doses accordingly <p>Details in DRUGDEX® ATORVASTATIN</p>
Pediatric Dose	<ul style="list-style-type: none">• Familial hypercholesterolemia: in boys and postmenarchal girls 10-17 yr, initially 10 mg ORALLY daily; titrate at 4-wk intervals up to MAX 20 mg ORALLY daily <p>Details in DRUGDEX® ATORVASTATIN</p>

Clinician can change search or select predefined links for additional information

Modalities of CDS

- 1. Reference knowledge selection and retrieval**
 - e.g., infobuttons, crawlers (indexing)
- 2. Information aggregation and presentation**
 - e.g., summaries, reports, dashboards
- 3. Data entry assistance**
 - e.g., forcing functions, calculations, evidence-based templates for ordering and documentation
- 4. Event monitors**
 - e.g., alerts, reminders, alarms
- 5. Care workflow assistance**
 - e.g., protocols, care pathways, practice guidelines
- 6. Descriptive or predictive modeling**
 - e.g., diagnosis, prognosis, treatment planning, treatment outcomes

Other CDS for medication ordering: workflow



Evidence for CDS (knowledge-based)

- Systematic review of 70 studies (RCTs), up to 2003
 - Evaluating the ability of CDS to improve clinical practice
 - Focus on 15 CDS features (derived from literature)
- CDS improved practice in **68%** of trials
 - Key features (independent predictors)
 - CDS as part of clinician **workflow**
 - **Recommendations** rather than just assessments
 - CDS at the **time** and **location** of decision making
 - CDS **triggered** by computerized **data** analysis
- *(CDS without patient-specific guidance)*

Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. *BMJ*. 2005;330(7494):765

“Point-of-care” information needs

- Information needs

- 47 physicians (self-reported)
 - 269 questions raised during 409 visits
 - » 2 questions for every 3 patients seen
 - Answers not pursued 70% of the time


Covell DG, Uman GC, Manning PR. Information needs in office practice: are they being met? *Ann Intern Med.* 1985 Oct;103(4):596-9.

- Frequent barriers

- Pursued answers only 55%
 - Doubt that an answer existed – lack of usable information
- Sources: colleague/peer (information consultation) and/or textbook (63%), electronic resource (16%)
 - Unable to find answer in 28%


Ely JW, Osheroff JA, Chambliss ML, Ebell MH, Rosenbaum ME. Answering physicians' clinical questions: obstacles and potential solutions. *J Am Med Inform Assoc.* 2005 Mar-Apr;12(2):217-24.

Scientific literature: knowledge explosion



“Survival” of clinically important evidence

Figure 2. Overall survival time (95% CI) free of signals for updating.



Systematic reviews
at risk, *n*

Years	0	2	4	6	8	10
at risk, <i>n</i>	100	73	59	34	14	6

Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D.
How quickly do systematic reviews go out of date? A survival
analysis. *Ann Intern Med.* 2007 Aug 21;147(4):224-33.

Context

Clinicians rely on systematic reviews for current, evidence-based information.


Contribution

This survival analysis of 100 meta-analyses indexed in *ACP Journal Club* from 1995 to 2005 found that new evidence that substantively changed conclusions about the effectiveness or harms of therapies arose frequently and within relatively short time periods. The median survival time without substantive new evidence for the meta-analyses was 5.5 years. Significant new evidence was already available for 7% of the reviews at the time of publication and became available for 23% within 2 years.

Implication


Clinically important evidence that alters conclusions about the effectiveness and harms of treatments can accumulate rapidly.


Evolution towards “Stratified Medicine”



Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. *Nat Rev Drug Discov.* 2007 Apr;6(4):287-93.

Routine testing for genetic differences

 U.S. Department of Health & Human Services

 **U.S. Food and Drug Administration**

A-Z Index

Search

go

Home | Food | Drugs | Medical Devices | Vaccines, Blood & Biologics | Animal & Veterinary | Cosmetics | Radiation-Emitting Products | Tobacco Products

Safety

Share Email this Page Print this page Change Font Size

Home > Safety > MedWatch The FDA Safety Information and Adverse Event Reporting Program > Safety Information

MedWatch The FDA Safety Information and Adverse Event Reporting Program

Safety Information

Safety Alerts for Human Medical Products

[2010 Safety Alerts for Human Medical Products](#)

[2009 Safety Alerts for Human Medical Products](#)

[2008 Safety Alerts for Human Medical Products](#)

[2007 Safety Alerts for Human Medical Products](#)

[2006 Safety Alerts for Human Medical Products](#)

[2005 Safety Alerts for Human Medical Products](#)

[2004 Safety Alerts for Human Medical Products](#)

Plavix (clopidogrel): Reduced effectiveness in patients who are poor metabolizers of the drug

Audience: Cardiology healthcare professionals, patients

[Posted 03/12/2010] FDA notified healthcare professionals and patients that a Boxed Warning has been added to the prescribing information for Plavix, an anti-blood clotting medication. The Boxed Warning in the drug label will include information to:

- Warn about reduced effectiveness in patients who are poor metabolizers of Plavix. Poor metabolizers do not effectively convert Plavix to its active form in the body.
- Inform healthcare professionals that tests are available to identify genetic differences in CYP2C19 function.**
- Advise healthcare professionals to consider use of other anti-platelet medications or alternative dosing strategies for Plavix in patients identified as poor metabolizers.

Plavix is given to reduce the risk of heart attack and death in patients with cardiovascular disease. Platelets, called platelets, making platelets less likely to clump together. For additional information for healthcare professionals, see the Plavix Safety Communication.

[03/12/2010 - Drug Safety Communication: Reduced Effectiveness of Plavix in Poor Metabolizers]

[03/12/2010 - Information on Clopidogrel Bisulfate]

Inform healthcare professionals that tests are available to identify genetic differences in CYP2C19 function.

Government incentives for CDS





Diagram adapted from Tang & Mostashari (chairs) et al., Meaningful Use Workgroup Presentation. HIT Policy Committee, June 16, 2009.

Learning Healthcare System




ONC & IOM:
Emphasis now on
the "**Electronic
infrastructure** for
continuous
learning and
quality-driven
health and health
care programs."

Clinical Knowledge Management System

Clinical Knowledge Management System





- **CKMS**: supports the implementation and management of computer-**accessible** and computer-**interpretable** clinical knowledge
 - Wide variety of knowledge assets
 - Overlapping knowledge asset lifecycles
 - Multiple deployment alternatives
 - ✓ Clinical Decision Support (CDS) modalities
 - ✓ Integrated with clinical care processes (“workflow”)



CDS implementation requirements

- ✓ Based on the **best evidence** available
- ✓ Covers problem in **detail** – problem solving, advice, explanations
- ✓ Readily **updatable** by clinician without unexpected effects
- ✓ Provides **links** to related local and Internet material
- ✓ System (knowledge) **performance** is validated against suitable gold standard
- ✓ Demonstrated practice or outcomes improvements in rigorous **study**
- ✓ **Clinician always in control**
 - Searching and browsing
 - Get help and explanations
 - Try out ‘what-if’ scenarios

Implementation of CDS modalities

CDS modality	Types of Knowledge Assets			
1. Reference knowledge selection and retrieval			Reference	
2. Information aggregation and presentation			Actionable	
3. Data entry assistance				
4. Event monitors				
5. Care workflow assistance			Executable	
6. Descriptive or predictive modeling				
				

Knowledge Lifecycle details

Medication rules and alerts

Generation

- New medications added to the enterprise dictionary (trigger)
- New requests from internal experts
- New information obtained from external reference sources

Acquisition

- Review of external reference sources (confirmation)
- Review of specialized literature (details)
- Validation with internal panel of experts (type of CDS alert)

Representation

- Creation of new rules and alerts: specialized editor (software)
- Validation of new rules and alerts using test data

Deployment


- Production release of new rules and alerts (software)
- Publication of the new rules (intranet portal)

Maintenance

- Comments received from users and internal experts
- Information obtained from external reference sources




Typical knowledge management lifecycle




KE – knowledge engineer (pharmacist, informatician)
SME – subject matter expert (pharmacist, physician, etc.)

Lifecycle models with “outsourcing”

**Knowledge
Content only**




**Knowledge
Services +
Content**




Both require content localization (configuration)

CKMS reality: concurrent lifecycles



CKMS reality: content dependencies



CKMS @ Partners HealthCare

- Enable all knowledge content to be **accessible**, **updatable**, and **maintained** with an **audit trail**
- Reduce the **cost** and increase **efficiency** of both design and implementation **maintenance**
- Enable **stakeholder involvement** in the design process to support effective adoption and use
- Ensure alignment with **quality**, **safety**, and **operating** business drivers (HPM, Joint Commission, etc.)
- Avoid potential **liability** of making incorrect or incomplete recommendations due to lack of **coverage** or **currency**

CKMS Components

Personnel

Domain
Experts

Knowledge
Engineers

Knowledge
Modelers

Terminology
Engineers

Framework

Lifecycle
Processes

Governance
Processes

Software
Platform

Assets

Knowledge &
Metaknowledge

Models &
Metamodels

Ontologies &
Concepts

CKMS: Personnel requirements

- Dedicated **multidisciplinary team**
 - analysis, clinical, informatics, modeling, process analysis, project management, resource management, etc.
- Excellent analytical and communication **skills**
- Extensive initial **training** with an emphasis on **continuous learning** and (virtual) **collaboration**
- Process and artifact **specialization**
 - CDS modality, clinical domain, asset type, maintenance
- Career orientation towards specific **job families**
 - Knowledge engineer, modeler, domain expert, etc.
- Proactive **recruiting** and **retention** policies




CKMS: Lifecycle requirements (1)

- **Integrated** support for all lifecycle phases
- Detailed **provenance** and consistent tracking of **dependencies**
- Configurable **process automation**
 - Reduce repetitive steps and improve content integrity
- Extensive **version, ownership, and access control**
 - Support for distributed curation
- Content **validation** services
 - Improve overall maintenance costs and consistency
- Analytical and user-initiated **feedback**
 - Continuously improve processes and content




CKMS: Lifecycle requirements (2)

- **Distributed and collaborative** curation
 - Asynchronous and synchronous activities
 - Minimize the overhead of consensus building (evaluation-driven)
 - Expediency with transparency
- Curation processes **loosely coupled** to utilization
 - Optimized for integration and effective maintainability
 - Repurposing for multiple interventions and systems (“**localization**”)
- **Active maintenance** (introspective)
 - Identify inconsistencies using structural and semantic inferences
 - Enable autonomous updates (propagation)
- Emphasis on projects with an **enterprise scope** (ROI)
 - Ability to host ‘local’ and ‘niche’ efforts (ensure maintainability)



CKMS: Governance requirements

- Clinical **vision** and **leadership** helping the organization understand the need (alignment)
 - Business strategies, government incentives, relevant regulations
- Detailed **business case** illustrating the opportunity
 - Emphasis on CKM as an efficient model for *knowledge translation*
- Identify **opportunities** that rely on knowledge-driven interventions
 - Quality, safety, disease management, protocol-based care
- Detailed **roadmap** emphasizing continuous **evaluation**
 - Improvement supported by change management procedures
- Stakeholders directly involved with **planning** and **execution**
 - Clinical leaders that provide appropriate accountability
 - Availability of clinical domain experts
 - Incentives for active participation



CKMS: Software platform requirements

- **Integration** – complete “workbench” that provides integrated content authoring, review, and publishing, while ensuring proper asset lifecycle management
- **Modularity** – component-based architecture that enables processes and content reuse, while ensuring proper management of dependencies
- **Configurability** – multiple concurrent lifecycle processes for authoring, reviewing, and publishing content, taking into account distinct content types and personnel roles
- **Extensibility** – new processes, tools, roles, metadata, and content can be added as needed without requiring platform changes
- **Compliance with standards** – content, processes, and models are represented (stored) using standard formats
- **Learning** – built-in utilization monitoring and analytical capabilities
- **Intelligence** – manage content with ‘meta-knowledge’



CKMS: Content (asset) requirements

- Authoritative **source** of clinical knowledge
 - Integrative view including ontologies, models, and knowledge (layers)
- Extensible **metadata**
 - Classification, lifecycle, and provenance processes
- Explicit representation **structural** and **semantic properties**
 - Using “meta-models” (logic-based) for multiple types of assets
- Explicit representation of **dependencies** and **associations**
 - Ensure integrity and enabling repurposing
- Ability to represent a growing number of unique (**individual**) combinations of **contextual characteristics**
 - Genes, proteins, cells, lifestyle, diet, environment, preferences, ...
- Extensive **mappings** to external reference sources to ensure optimal interoperability



CKMS

Challenges & Opportunities

Expected benefits of a CKMS

- Improved **efficiency** and **reliability** of knowledge content creation and maintenance processes
 - Standardize and unify content authoring
 - Eliminate redundant content editing (manual)
 - Proper management of content dependencies
 - Appropriate use of reference content sources
 - Streamline communication: engineers, domain experts, and knowledge workers
 - Implementation of automated content validation processes
- Improve overall knowledge content **accuracy, completeness, and maintainability**
 - Reduce any potential risks to patients due to incorrect and/or outdated content

Overview of general KM trends

Creation	Specialists → Everyone, collaborative activity
Integration	At design time → At use time (ongoing)
Dissemination	Lecture, broadcasting, classroom → On demand, integration of learning and working, relevant to tasks, personalized
Learning paradigm	Knowledge transfer → Knowledge construction
Social structures	Individuals, top-down → Communities of practice , peer-to-peer
Work style	Standardize → Im provis
Information spaces	Closed, static → Open, dynamic
Breakdowns	Errors to be avoided → Opportunities for innovation and learning
Tasks	System driven → User or task driven

Fischer G & Ostwald J. Knowledge Management: Problems, Promises, Realities, and Challenges.
IEEE Intelligent Systems, January/February 2001, 60-72, 2001.

CKMS: implementation challenges

- Clinical **governance** and **stewardship** is poorly defined
 - Liability from outdated or incorrect knowledge not recognized
 - Cost of not having knowledge/CDS is not frequently considered
- **Projects** and **resources** defined in competition with activities
 - Clinical experts frequently unavailable (limited commitment)
 - Processes for creating & vetting knowledge not clearly defined
- **Maintenance** of knowledge assets is an afterthought
 - Knowledge once deployed for use is not easily accessible ('locked')
 - Software tools frequently ignore content dependencies and lifecycle
 - Long-term commitment to content maintenance is underestimated
- **Analytics** – impact on processes and outcomes not available

Availability of data

- Availability of **structured** and **coded** clinical data determines the feasibility of CDS interventions
 - Data is expensive to generate at the point-of-care (systematically)
 - Benefits frequently not tangible to data “producers” (extra incentives)
- **Dissemination** and **exchange** of knowledge assets depends on **data standardization** (structure & semantics)


Natural language processing?

Voice recognition?

Mobile devices?


Knowledge-driven documentation?

Semantic expressivity (adaptive)?




Cognitive aspects of CKMS/CDS tools

“Technologies mediate the decision-making process in distinct and often counterintuitive ways that can produce unintended consequences.”¹



Attention economy – “we have more information available than we have attention to understand and apply it. At the same time, finding information relevant to the task at hand is becoming increasingly critical.”²



“Decision technology does not merely facilitate or augment decision-making rather it reorganizes decision-making practices.”¹

(1) Patel VL, Kaufman DR, Arocha JF. Emerging paradigms of cognition in medical decision-making. *J Biomed Inform.* 2002 Feb;35(1):52-75.

(2) Fischer G & Ostwald J. Knowledge Management: Problems, Promises, Realities, and Challenges. *IEEE Intelligent Systems*, January/February 2001, 60-72, 2001.

Context modeling

- “The real challenge is to **“say the right thing at the right time in the right way.”** This is possible only with computational environments that take the **user’s context** into account.”
 - What the users are doing?
 - What they have done?
 - Where they are?
 - What they know?
 - ...

Clinician

Patient


Process

Setting

System

Resources

Efficient dissemination strategy



Current dissemination barriers

Large scale CKMS



What will differentiate clinical systems?

Process automation?

Ease of use?

Advanced CDS functions?

[Home](#)

[About the Portal](#)

[About the Consortium](#)

[FAQ](#)

[Glossary](#)

[Terms of Use](#)

[Contact Us](#)

Search Term :

diabetes

[Search](#)

[Clear Selection](#)



[Show Advanced Search](#)



[Collapse Results](#)

<http://cdsportal.partners.org>

Title:

 [PHS Diabetes Guidelines 2009 L1](#)

Specification Level

Level 1 - Unstructured

Contributing Entity

Partners Healthcare Systems

Content Type

Reference

Description:

Clinical Guidelines for Treatment of Type 2 Diabetes in Non-Pregnant Adults, Feb 2009. Criteria for Diagnosis, Treatment Goals, Recommended Frequency of Diabetes Care Components, and Glycemia, LDL, & Hypertension Management for the Non-Pregnant Adult

[Show Details..](#)

Title:

 [CDSC Diabetes L3](#)

 [Open as XML](#)

Specification Level

Level 3 - Structured

Contributing Entity

Partners Healthcare Systems

Content Type

Reminder

Description:

Content contains 8 discrete reminders for screening, surveillance, and prevention of diabetic complications.

[Show Details..](#)

Title:

 [PHS Classification Rules L3](#)

 [Open as XML](#)

Specification Level

Level 3 - Structured

Contributing Entity

Partners Healthcare Systems

Content Type

Definition/Dictionaries

Description:


Classification Rule Definitions design by Partners Health Care

[Show Details..](#)

Title:

 [CDSC Diabetes L2](#)

Integration of related KM systems



Factors justifying a CKMS

- **Quantity of knowledge (explosion)**
 - Evolution towards stratified/personalized clinical practice
 - Complex decision making process demanding computerized support
- **Distributed care delivery processes (fragmented)**
 - Extensive knowledge is needed beyond organizational boundaries
 - Learning opportunities leading to optimal care and stewardship
- **Global trends towards knowledge socialization**
 - Consumers (patients) constantly seeking knowledge (empowerment)
 - Shared responsibility only possible with proper understanding
- **Knowledge content maintainability (long-term)**
 - Diversity and quantity makes traditional (manual) curation unrealistic
 - Increasing number (complexity) of dependencies across lifecycles and biomedical domains

Acknowledgements

Blackford Middleton

Tonya Hongsermeier

Saverio Maviglia

Beatriz Rocha

CIRD/KM Team at Partners

John Doole

Fay Moy

Additional references

- Book “[Clinical decision support: the road ahead](#)”
 - Greenes RA, editor. Academic Press, 2006.
- Paper “[Ten commandments for effective clinical decision support](#): making the practice of evidence-based medicine a reality.”
 - Bates DW, Kuperman GJ, Wang S, Gandhi T, Kittler A, Volk L, Spurr C, Khorasani R, Tanasijevic M, Middleton B. J Am Med Inform Assoc. 2003 Nov-Dec;10(6):523-30. (PMID: 12925543)
- Paper “[A roadmap for national action on clinical decision support](#).”
 - Osheroff JA, Teich JM, Middleton B, Steen EB, Wright A, Detmer DE. J Am Med Inform Assoc. 2006 Jul-Aug;13(4):369-71. (PMID: 17213487)
- Paper “[Just-in-time delivery comes to knowledge management](#).”
 - Davenport TH, Glaser J. Harv Bus Rev. 2002 Jul;80(7):107-11, 126. (PMID: 12140850)
- Paper “[Using commercial knowledge bases for clinical decision support](#): opportunities, hurdles, and recommendations.”
 - Kuperman GJ, Reichley RM, Bailey TC. J Am Med Inform Assoc. 2007 Mar-Apr;14(2):141-5. (PMID: 16622160)
- Paper “[Predictive data mining in clinical medicine](#): current issues and guidelines.”
 - Bellazzi R, Zupan B. Int J Med Inform. 2008 Feb;77(2):81-97 (PMID: 17188928)
- Web site “[Open Clinical](#)” (UK): <http://www.openclinical.org/>

Thank you!

Roberto A. Rocha, MD, PhD
rarocho@partners.org